相关实验视频

Updated: Feb 26, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

在向FLT3治疗急性髓性白血病治疗方面,不断发展的范式

Rajan Thapa¹, Jesus Shrestha², Keshav Raj Paudel³

¹Department of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.

Trends in pharmacological sciences

|February 24, 2026

概括

针对FLT3突变对于急性髓性白血病 (AML) 治疗至关重要. 选择性抑制剂和蛋白质降解剂等新疗法提供了更好的疗效,并解决了AML的耐药性和毒性挑战.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

类似FMS的氨酸激酶3 (FLT3) 突变是急性髓性白血病 (AML) 发病的关键驱动因素.
异常的FLT3信号促进白血病细胞的增殖和生存.
目前的FLT3抑制剂面临的挑战是药物耐药性和非向毒性.

研究的目的:

审查FLT3突变在AML进展中的作用.
讨论现有的FLT3抑制剂的局限性.
探索FLT3突变AML的新兴治疗策略.

主要方法:

对AML中FLT3抑制剂的临床前和临床研究的文献综述.
对新出现的治疗方式的分析,包括选择性抑制剂,向蛋白质溶解的嵌合体 (PROTACs) 和蛋白质降解剂.
评估组合疗法的潜力.

主要成果:

FLT3突变是AML发展和进展的重要因素.
现有的FLT3抑制剂显示出临床活性,但由于耐药性和毒性而受到限制.
选择性抑制剂和蛋白质降解剂等新的方法显示出增强功效和持续目标抑制的希望.
新兴的策略为克服当前治疗挑战和改善FLT3突变AML的结果提供了潜力.

结论:

抑制FLT3仍然是治疗AML的关键策略.
新兴的治疗方法代表了基于精度的进步,提供了更高的疗效和更好的安全性.
对选择性抑制剂,PROTACs和蛋白质降解剂的进一步研究是有必要的,以优化AML治疗.

关键词:

FLT3 抑制剂的使用.急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.抗体 - 药物联合体药物耐药性耐药性药物耐药性

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...